Cytonet GmbH

What Cytonet GmbH does

Cytonet GmbH is described in available firmographic records as an international biotechnology company founded in 2000, operating from sites in Weinheim, Germany and Durham, NC, USA, with a reported headcount of 51-100 employees. The input contains no disclosed products, therapeutic pipeline, technology platform, or commercial customers associated with the entity itself.

All granular data points supplied alongside the firmographic record (product listings, technology descriptions, revenue figures, customer segments, marketing channels, and a contact address for SEG Host) actually describe a third-party domain-name marketplace listing for "cytonet.de" on elitedomains.de. The German-language page attached is a parked "domain for sale" notice operated by SEG Host, not a corporate website of Cytonet GmbH. This represents a fundamental data conflict that prevents reliable assessment of the company's actual business model, revenue mechanics, pricing approach, or customer base. What can be stated with evidence is that the company holds a German corporate identity with a stated US site, was founded in the year 2000, and that its primary German web domain is currently offered for sale rather than operated as an active corporate property.

Name

Cytonet GmbH

Legal name

Cytonet GmbH

Website

https://cytonet.de

Company type

Private

Founded year

2000

Operating status

Unknown

Headcount range

51–100 employees

Short description

Cytonet GmbH is a privately held German biotechnology firm, founded in 2000, with stated sites in Weinheim, Germany and Durham, NC, USA, and 51-100 employees. No products, pipeline, or commercial customers are documented in the available data.

Ownership category

akta.pro rank

Headquarters

HQ city

Weinheim

HQ country

Germany

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Others

Distribution channels1 record

Marketing channels3 records

Core offering

Cytonet GmbH's primary observable offering is the sale of its premium .de domain 'cytonet.de' through the SEG Host domain marketplace. The transaction is facilitated by SEG Host's escrow service, which handles authentication code (Auth-Code) transfer, secure payment processing, neutral domain valuation, and includes a 100% money-back guarantee. No active products, services, or ongoing business operations are evident beyond this single domain sale.

Product overview

No product or service information available. The source content pertains to a domain marketplace listing (cytonet.de) being offered for sale by SEG Host, not information about Cytonet GmbH's actual business offerings, products, or services.

Differentiator

Problem solved

Functional benefit

Products and services

• cytonet.de premium .de domain

Segments2 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators1 record

Recent moves2 records

Expansion highlights1 record

Emerging players

• Cytori Therapeutics: Cell-therapy company focused on adipose-derived regenerative cells — comparable small-cap, late-clinical-stage cell-therapy peer.
• Holostem Terapie Avanzate: Italian developer of epithelial stem-cell therapies for severe ocular burns — a small-to-mid European cell-therapy biotech with comparable scope and stage.
• Capricor Therapeutics: U.S.-based cell and exosome therapy developer — comparable small-cap cell-therapy peer with cross-border clinical programs.
• Pluristem Therapeutics: Israel-based cell-therapy developer using placental-derived cell platforms — comparable small-cap cell-therapy peer with similar international footprint.
• Anterogen Co., Ltd. Korean biotech developing cell therapies (including adipose-derived stem cells) for inflammatory and autoimmune conditions — comparable small-cap cell-therapy peer.

Others

• Stemcell Technologies: Cell-therapy tools and reagents provider serving biotech researchers — adjacent enabling supplier to the cell-therapy R&D ecosystem rather than a direct competitor.

Broad incumbents

• Mesoblast Limited: Established commercial-stage cell-therapy company developing mesenchymal stem cell platforms — broader incumbent in the same cell-therapy category as a smaller biotech peer.
• TiGenix (now part of Takeda): Belgian cell-therapy company (acquired by Takeda) that commercialized an allogeneic cell therapy — representative of where small European cell-therapy peers have exited to large pharma.

Direct peers

• Promethera Biosciences (now Liver Therapeutics): Belgian/German cell-therapy company focused on liver cell therapies — directly comparable to a biotech with Weinheim/Durham operations working on cell-based therapeutics in the liver/cellular space.
• Orgenesis Inc. Cell and gene therapy company with transatlantic operations developing autologous cell therapies — comparable in stage, international footprint, and cell-therapy orientation to a mid-sized European biotech.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat1 record

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cytonet GmbH